Donald T Corson

Title: The Innovative Contributions of Donald T. Corson

Introduction: Donald T. Corson, an accomplished inventor located in Boulder, Colorado, has made significant contributions to the field of pharmaceuticals. With a total of seven patents to his name, Corson's work primarily focuses on the development of selective HER2 inhibitors, which are crucial in cancer treatment.

Latest Patents: One of Donald T. Corson's latest patents concerns the polymorphs of ARRY-380, a selective HER2 inhibitor, and the pharmaceutical compositions that contain them. The detailed patent outlines processes for preparing these polymorphs as well as the pharmaceutical compositions comprising them. Specifically, this also includes polymorphs of N4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-N6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine, showcasing the innovative approaches to drug formulation and delivery.

Career Highlights: Throughout his career, Corson has worked with prominent companies in the biotech industry, including Array Biopharma Inc. and Constellation Pharmaceuticals, Inc. His experience in these organizations has enabled him to refine his skills in drug development and patenting innovative pharmaceutical solutions.

Collaborations: In his journey as an inventor, Corson has collaborated with notable coworkers, including Christopher M. Lindemann and Daniel John Watson. These partnerships have likely enhanced the breadth of his research and development endeavors, leading to groundbreaking discoveries in the pharmaceutical sector.

Conclusion: Donald T. Corson exemplifies what it means to be an innovative inventor in the modern pharmaceutical landscape. With seven patents under his belt, including significant contributions to selective HER2 inhibitors, his work serves as a testament to the critical role inventors play in advancing medical science. As he continues to innovate, the impact of his research will undoubtedly be felt in the years to come.